FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/01/2026
Voltar para busca
Dado oficial do USPTO
ENDOPORE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ENDOPORE
ST13
US500000079379326Classe
5, 35, 42, 44
Pedido
79379326
Registro
7805555
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 42, 44
Data de depósito
25/07/2023
Data de registro
27/05/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/05/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
HARMON, RAYMOND E
Unidade examinadora
L30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
VITARKA THERAPEUTICS LTD
Representantes
Jordan Arnot Leahey CM Law PLLC
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for intracellular delivery of drugs for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of drugs for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of nucleic acids for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of proteins for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of proteins for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of small molecules for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of small molecules for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of drugs for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of therapeutic substances for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of proteins for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of small molecules for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical compositions and preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer
Classe 35
Compilation of information into computer databases in the medical field
Classe 42
Scientific and technological servicesscientific researchtechnological researchresearch and designall in the fields of intracellular delivery of drugsgene editingintracellular delivery of therapeutic substances focused on the development of RNA therapiesintracellular delivery of therapeutic substances focused on non-viral delivery technologyintracellular delivery of nucleic acidsintracellular delivery of proteinsintracellular delivery of peptidesintracellular delivery of small molecules; research services in the fields of intracellular delivery of drugsgene editingintracellular delivery of therapeutic substances focused on the development of RNA therapiesintracellular delivery of therapeutic substances focused on non-viral delivery technologyintracellular delivery of nucleic acidsintracellular delivery of proteinsintracellular delivery of peptidesintracellular delivery of small molecules; clinical trialsscientific research in the nature of conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; medical researchservices for assessing the efficacy of pharmaceuticals; informationadvisory and consultancy services relating to all of the aforesaid
Classe 44
Medical services; medical analysis for the diagnosis and treatment of persons; pharmacy advicepreparation of prescriptions in pharmacies and providing medical advice related to pharmaceutics; advisory services relating to health; advisory services relating to medical services; health carearranging of medical treatment; consultancy relating to health care; health advice and information services; health care; health care services; health centres being health clinic services; health clinic services; information services relating to health care; medical information retrieval services; health caremedical treatment services; medical health assessment services; health carepreparation of reports relating to health care matters; professional consultancy relating to health; providing health information; provision of health care services; provision of medical services; provision of medical information relating to medical practitioners; provision of medical information relating to medical specialists; services for the provision of medical care information; informationadvisory and consultancy services relating to all of the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
21/12/2025
FIMP
FINAL DISPOSITION PROCESSED
21/12/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/05/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
27/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/04/2025
PUBO
PUBLISHED FOR OPPOSITION
08/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/03/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
14/03/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/03/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
14/03/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/03/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/03/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/02/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
20/02/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
15/01/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
14/11/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
14/10/2024
GNFR
FINAL REFUSAL E-MAILED
14/10/2024
CNFR
FINAL REFUSAL WRITTEN
14/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/09/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/09/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/09/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/09/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
02/08/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
19/07/2024
RFNT
REFUSAL PROCESSED BY IB
08/05/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/04/2024
RFRR
REFUSAL PROCESSED BY MPU
17/04/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
31/03/2024
CNRT
NON-FINAL ACTION WRITTEN
30/03/2024
DOCK
ASSIGNED TO EXAMINER
27/03/2024
MAFR
APPLICATION FILING RECEIPT MAILED
26/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/09/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/09/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ENDOPORE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.